NO20031471L - Glykoformer av faktor VII - Google Patents

Glykoformer av faktor VII

Info

Publication number
NO20031471L
NO20031471L NO20031471A NO20031471A NO20031471L NO 20031471 L NO20031471 L NO 20031471L NO 20031471 A NO20031471 A NO 20031471A NO 20031471 A NO20031471 A NO 20031471A NO 20031471 L NO20031471 L NO 20031471L
Authority
NO
Norway
Prior art keywords
factor vii
glycoforms
vii glycoforms
factor
asparagine
Prior art date
Application number
NO20031471A
Other languages
English (en)
Other versions
NO20031471D0 (no
Inventor
Hans Kurt Pingel
Niels Kristian Klausen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27439823&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20031471(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of NO20031471D0 publication Critical patent/NO20031471D0/no
Publication of NO20031471L publication Critical patent/NO20031471L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse vedrører preparater som omfatter faktor VU og andre blodkoagulasjonsfaktorer med endrede mønstre for asparaginbundet glykosylering.
NO20031471A 2000-10-02 2003-04-01 Glykoformer av faktor VII NO20031471L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200001456 2000-10-02
DKPA200100262 2001-02-16
DKPA200100430 2001-03-14
DKPA200100751 2001-05-14
PCT/DK2001/000633 WO2002029025A2 (en) 2000-10-02 2001-10-02 Factor vii glycoforms

Publications (2)

Publication Number Publication Date
NO20031471D0 NO20031471D0 (no) 2003-04-01
NO20031471L true NO20031471L (no) 2003-05-30

Family

ID=27439823

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031471A NO20031471L (no) 2000-10-02 2003-04-01 Glykoformer av faktor VII

Country Status (18)

Country Link
US (6) US20020151471A1 (no)
EP (6) EP1325127B1 (no)
JP (4) JP4477299B2 (no)
KR (2) KR100880624B1 (no)
CN (3) CN1468303B (no)
AT (2) ATE425254T1 (no)
AU (5) AU2001291651A1 (no)
BR (2) BR0114373A (no)
CA (2) CA2422214A1 (no)
CZ (1) CZ2003718A3 (no)
DE (2) DE60137950D1 (no)
ES (2) ES2323761T3 (no)
HU (2) HUP0301267A3 (no)
IL (2) IL154879A0 (no)
MX (1) MXPA03002853A (no)
NO (1) NO20031471L (no)
PL (2) PL361017A1 (no)
WO (4) WO2002029045A2 (no)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
SI1308455T1 (sl) 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
RU2278123C2 (ru) * 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
HUP0402158A2 (hu) 2001-10-02 2005-01-28 Novo Nordisk Health Care Ag Rekombináns fehérjék előállítási eljárása eukarióta sejtekben
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
SI1499719T1 (sl) * 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
UA86744C2 (en) * 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
ES2523655T5 (es) * 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
US20060166874A1 (en) * 2002-09-30 2006-07-27 Haaning Jesper M Fvii or fviia variants having increased clotting activity
WO2004082708A2 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
CA2519020A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Method for the production of gla-residue containing serine proteases
DK2085470T3 (da) * 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
CN1839203B (zh) * 2003-06-19 2011-11-16 拜耳医药保健有限公司 因子VII或VIIa的GLA结构域变体
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
AU2004252028B2 (en) * 2003-06-30 2008-05-08 Glytech, Inc. Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
CN102872451A (zh) * 2003-08-14 2013-01-16 诺和诺德医疗保健公司 因子vii多肽类的含水液体药物组合物
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
WO2005035748A1 (en) 2003-10-10 2005-04-21 Novo Nordisk Health Care Ag Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP2189523B1 (en) * 2003-10-14 2012-01-04 Baxter International Inc. Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
PL1711513T3 (pl) 2003-12-01 2014-12-31 Novo Nordisk Healthcare Ag Nanofiltracja roztworów czynnika vii w celu usunięcia wirusów
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
RU2373953C2 (ru) * 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
WO2005068620A1 (en) * 2004-01-07 2005-07-28 Novo Nordisk Health Care Ag Method for the production of recombinant proteins
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
RU2396347C2 (ru) * 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
JP2008514216A (ja) * 2004-09-29 2008-05-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｄｅｓｇｌａ−ｖｉｉ因子ポリペプチド構造の除去による、ｖｉｉ因子ポリペプチドの原体の精製
SI2586456T1 (sl) 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
WO2006067116A1 (en) * 2004-12-21 2006-06-29 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
ES2395544T3 (es) * 2004-12-23 2013-02-13 Novo Nordisk Health Care Ag Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
EP1851305B1 (en) * 2005-02-11 2012-01-18 Novo Nordisk Health Care AG Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
JP2008531026A (ja) 2005-02-28 2008-08-14 バクスター・インターナショナル・インコーポレイテッド ビタミンｋ依存性タンパク質発現を改善するための、ビタミンｋエポキシドレダクダーゼサブユニット１の組換え同時発現
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
CN101198696B (zh) 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
PT1969127E (pt) * 2005-12-21 2014-09-23 Univ North Carolina Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US8461115B2 (en) 2006-03-16 2013-06-11 Stellaris Pharmaceuticals Aps Methods for local treatment with factor VII
PL2007885T3 (pl) * 2006-04-11 2010-12-31 Csl Behring Gmbh Sposób zwiększania odzysku peptydów terapeutycznych in vivo
FR2901707B1 (fr) * 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
JP5122562B2 (ja) * 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
JP5167449B2 (ja) * 2006-11-07 2013-03-21 独立行政法人科学技術振興機構 直鎖状核酸分子懸架支持体、直鎖状核酸分子伸長方法および直鎖状核酸分子標本
DK2101821T3 (da) * 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2099475B1 (en) * 2007-01-03 2016-08-24 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor viia-related polypeptides
ES2406267T3 (es) 2007-04-03 2013-06-06 Biogenerix Ag Métodos de tratamiento usando G-CSF glicopegilado
PL2147096T3 (pl) * 2007-04-13 2015-08-31 Catalyst Biosciences Inc Zmodyfikowane polipeptydy czynnika VII i ich zastosowania
EP2139499A4 (en) * 2007-04-26 2010-05-05 Inspiration Biopharmaceuticals RECOMBINANT VITAMIN K-DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHOD FOR THE PRODUCTION THEREOF
AU2014202989B2 (en) * 2007-04-26 2016-07-07 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
AU2016238889B2 (en) * 2007-04-26 2019-06-27 Aptevo Biotherapeutics Llc Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
EP2014299A1 (en) * 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN105816858A (zh) 2007-12-28 2016-08-03 巴克斯特国际公司 重组vwf配方
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
AU2009307648C1 (en) 2008-10-21 2016-12-08 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
HUE026210T2 (en) * 2008-11-12 2016-05-30 Baxalta Inc Procedure for serum-free, insulin-free VII. factor
JP5027106B2 (ja) * 2008-12-25 2012-09-19 一般財団法人阪大微生物病研究会 日本脳炎ウイルス抗原
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
EP2494040B1 (en) * 2009-10-30 2018-08-29 Aptevo BioTherapeutics LLC Method of producing recombinant vitamin k dependent proteins
WO2011069056A2 (en) * 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
WO2012075138A1 (en) * 2010-11-30 2012-06-07 Progenetics Llc Method of producing biologically active vitamin k dependent proteins in transgenic animals
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014057068A1 (en) 2012-10-10 2014-04-17 Novo Nordisk Health Care Ag Liquid pharmaceutical composition of factor vii polypeptide
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016023893A2 (pt) * 2014-04-16 2017-08-15 Cmc Biologics As processo de fermentação por extração e preenchimento a alta densidade celular
ES2709994T3 (es) 2014-06-04 2019-04-22 Amgen Inc Métodos de recolección en cultivos de células de mamífero
US9714302B2 (en) 2014-10-10 2017-07-25 W. R. Grace & Co.—Conn. Process for preparing spherical polymerization catalyst components for use in olefin polymerizations
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2017025566A1 (en) * 2015-08-10 2017-02-16 Glycotope Gmbh Improved recombinant factor vii
ES2803773T3 (es) * 2015-12-02 2021-01-29 CSL Behring Lengnau AG Medios mejorados para la expresión de proteínas recombinantes dependientes de vitamina k
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189534A (en) * 1976-11-11 1980-02-19 Massachusetts Institute Of Technology Cell culture microcarriers
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
US4335215A (en) * 1980-08-27 1982-06-15 Monsanto Company Method of growing anchorage-dependent cells
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
SE464816B (sv) * 1985-10-15 1991-06-17 Nilsson Kjell Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning
GB2184759B (en) * 1985-12-28 1990-07-18 Shimizu Construction Co Ltd Concrete-filled tubular steel piece, concrete-filled steel tube column and method of constructing same.
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
JPH01502080A (ja) * 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
EP0540650A1 (en) 1990-07-23 1993-05-12 Zymogenetics, Inc. Gamma-carboxylase and methods of use
ATE158816T1 (de) * 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
JP3459416B2 (ja) * 1991-02-28 2003-10-20 ザイモジェネティクス，インコーポレイティド 修飾されたファクター▲ｖｉｉ▼
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5268275A (en) * 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
IL104385A (en) * 1992-01-17 1995-12-31 Applied Research Systems Method and device for growing biomass particles
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
WO1993022448A1 (en) * 1992-05-01 1993-11-11 Teijin Limited Fed batch culture method for protein secreting cells
DE4221863C2 (de) 1992-07-03 1997-04-17 Stockhausen Chem Fab Gmbh Copolymere der Allyliminodiessigsäure mit ungesättigten Carbonsäuren und deren Verwendung als Komplexbildner, Peroxidstabilisatoren, Builder in Wasch- und Reinigungsmitteln und Dispergatoren
US5510328A (en) * 1994-04-28 1996-04-23 La Jolla Cancer Research Foundation Compositions that inhibit wound contraction and methods of using same
WO1998004680A1 (en) * 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
PT973544E (pt) * 1997-04-08 2001-12-28 Baxter Ag Preparacao de complexo de protrombina imunotolerante
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
ATE408020T1 (de) * 1998-11-06 2008-09-15 Novo Nordisk Healthcare Ag Verfahren zur herstellung von faktor vii
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
JP2003506077A (ja) * 1999-08-05 2003-02-18 バクスター アクチェンゲゼルシャフト 組換え安定細胞クローン、その産生およびその使用
UA74557C2 (en) * 1999-09-03 2006-01-16 Applied Research Systems A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers
WO2001081573A1 (en) * 2000-04-26 2001-11-01 Aventis Pharma Deutschland Gmbh Edg8 receptor, its preparation and use

Also Published As

Publication number Publication date
WO2002029025A9 (en) 2003-05-15
CA2422214A1 (en) 2002-04-11
WO2002029025A3 (en) 2002-10-10
WO2002029083A2 (en) 2002-04-11
HUP0301267A2 (hu) 2003-09-29
DE60137950D1 (de) 2009-04-23
ATE465253T1 (de) 2010-05-15
EP1325127A2 (en) 2003-07-09
MXPA03002853A (es) 2005-05-16
DE60141908D1 (de) 2010-06-02
US6903069B2 (en) 2005-06-07
AU9165201A (en) 2002-04-15
EP1325113B1 (en) 2010-04-21
KR100861470B1 (ko) 2008-10-02
HUP0301267A3 (en) 2005-12-28
WO2002029045A2 (en) 2002-04-11
JP4477299B2 (ja) 2010-06-09
WO2002029045A3 (en) 2002-10-10
ATE425254T1 (de) 2009-03-15
AU2001295431A1 (en) 2002-04-15
HUP0301245A3 (en) 2005-12-28
ES2323761T3 (es) 2009-07-24
CN102766668B (zh) 2016-03-16
EP1356074A2 (en) 2003-10-29
BR0114374A (pt) 2003-12-30
EP2311943A3 (en) 2011-05-04
CA2422216C (en) 2010-03-16
IL154879A0 (en) 2003-10-31
CN1468303B (zh) 2012-07-18
BR0114373A (pt) 2004-02-17
PL361017A1 (en) 2004-09-20
JP2004510436A (ja) 2004-04-08
US20040058413A1 (en) 2004-03-25
CN1481438A (zh) 2004-03-10
EP2311943A2 (en) 2011-04-20
ES2344887T3 (es) 2010-09-09
AU2001291652B2 (en) 2007-09-13
JP2004512835A (ja) 2004-04-30
KR20030034245A (ko) 2003-05-01
WO2002029025A2 (en) 2002-04-11
KR100880624B1 (ko) 2009-01-30
EP1325127B1 (en) 2009-03-11
US20070122884A1 (en) 2007-05-31
PL361058A1 (en) 2004-09-20
WO2002029084A3 (en) 2002-09-26
EP1325147A2 (en) 2003-07-09
CZ2003718A3 (cs) 2003-08-13
HUP0301245A2 (hu) 2003-09-29
IL154880A0 (en) 2003-10-31
EP2261330A1 (en) 2010-12-15
JP4361730B2 (ja) 2009-11-11
CN102766668A (zh) 2012-11-07
US8202973B2 (en) 2012-06-19
US20020151471A1 (en) 2002-10-17
US20090281022A1 (en) 2009-11-12
WO2002029083A3 (en) 2003-08-21
CN1468303A (zh) 2004-01-14
EP1325113A2 (en) 2003-07-09
CA2422216A1 (en) 2002-04-11
KR20030081310A (ko) 2003-10-17
NO20031471D0 (no) 2003-04-01
AU2001291651A1 (en) 2002-04-15
JP2004510439A (ja) 2004-04-08
WO2002029084A2 (en) 2002-04-11
US20050075289A1 (en) 2005-04-07
AU2001291653A1 (en) 2002-04-15
US20020137673A1 (en) 2002-09-26
JP2004510786A (ja) 2004-04-08

Similar Documents

Publication Publication Date Title
NO20031471L (no) Glykoformer av faktor VII
DE60123389D1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
DK1200418T3 (da) Nematodicide trifluorbutener
SE0102315D0 (sv) Compounds
ATE358669T1 (de) Pyrazolderivate zur behandlung von hiv
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
TR200400072T4 (tr) Novel Biarylcarboxamides Biarylcarboxamide Nouveaux Biarylcarboxamides
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
BR0111451A (pt) Inibidores de serina protease
PL370134A1 (en) Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
ATE302017T1 (de) Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
ATE413375T1 (de) Retinoide zur behandlung von emphysem
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
DE60204584D1 (de) Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
DE50206761D1 (de) Fluorhaltige copolymere, deren herstellung und verwendung
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
DE60208701D1 (de) Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application